Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi Sells 5,679 Shares

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CTO David Badawi sold 5,679 shares of the firm's stock in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of $4.17, for a total transaction of $23,681.43. Following the transaction, the chief technology officer owned 1,831,025 shares in the company, valued at approximately $7,635,374.25. This trade represents a 0.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Sight Sciences Price Performance

Shares of NASDAQ:SGHT traded down $0.09 during midday trading on Thursday, hitting $3.43. 81,120 shares of the stock were exchanged, compared to its average volume of 210,446. The stock has a market cap of $177.32 million, a P/E ratio of -3.50 and a beta of 2.47. The company has a current ratio of 10.47, a quick ratio of 9.99 and a debt-to-equity ratio of 0.51. Sight Sciences, Inc. has a twelve month low of $2.03 and a twelve month high of $8.45. The company has a 50 day moving average price of $3.73 and a 200-day moving average price of $3.14.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01. The business had revenue of $17.51 million during the quarter, compared to the consensus estimate of $16.51 million. Sight Sciences had a negative return on equity of 54.62% and a negative net margin of 63.24%. On average, research analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SGHT. Rhumbline Advisers grew its holdings in Sight Sciences by 9.5% in the 1st quarter. Rhumbline Advisers now owns 49,797 shares of the company's stock valued at $120,000 after buying an additional 4,319 shares during the period. American Century Companies Inc. raised its position in shares of Sight Sciences by 10.7% during the 4th quarter. American Century Companies Inc. now owns 51,564 shares of the company's stock valued at $188,000 after acquiring an additional 4,964 shares in the last quarter. Wells Fargo & Company MN increased its position in Sight Sciences by 53.4% in the fourth quarter. Wells Fargo & Company MN now owns 16,600 shares of the company's stock worth $60,000 after buying an additional 5,781 shares during the period. Barclays PLC increased its holdings in shares of Sight Sciences by 11.9% during the fourth quarter. Barclays PLC now owns 56,294 shares of the company's stock valued at $205,000 after purchasing an additional 5,994 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of Sight Sciences by 2.1% during the fourth quarter. Northern Trust Corp now owns 332,491 shares of the company's stock valued at $1,210,000 after purchasing an additional 6,727 shares during the period. Institutional investors and hedge funds own 55.51% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on SGHT shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Sight Sciences in a report on Wednesday, April 9th. Citigroup reaffirmed a "neutral" rating and set a $3.60 price target (up from $3.20) on shares of Sight Sciences in a report on Thursday, May 22nd. Wall Street Zen raised Sight Sciences from a "sell" rating to a "hold" rating in a report on Saturday, June 28th. Lake Street Capital increased their price target on Sight Sciences from $2.50 to $3.00 and gave the stock a "hold" rating in a report on Friday, May 9th. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $4.00 price target (up from $3.50) on shares of Sight Sciences in a report on Wednesday, June 18th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, Sight Sciences has an average rating of "Hold" and an average price target of $4.10.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.